Zelira Therapeutics : Appendix 4D & FY22 Interim Financial Report

Appendix 4D

only

1.

Company Details

Name of Entity

Zelira Therapeutics Limited

ABN

Half year ended ("current period")

Half year ended ("previous period")

use

27 103 782 378

31 December 2021

31 December 2020

2.

Results for announcement to the market

AUD $

2.1 Revenues from ordinary activities

Up

700% to

727,699

personal

2.2 Profit / (loss) from ordinary activities after tax

attributable to members - 31 December 2020: loss of

Down

56% to

(5,613,420)

($3,594,626)

2.3 Net profit / (loss) for the period attributable to

Down

56% to

(5,613,420)

members - 31 December 2020: loss of ($3,594,626)

2.4 Dividends

Amount per security

Franked amount per security

Interim dividend declared

N/A

N/A

2.5 Record date for determining entitlements to the dividend

N/A

2.6 Brief explanation of any of the figures in 2.1 to 2.4 above necessary to enable figures to be

understood

Commercialisation continued to ramp up during the period with sales momentum gaining for current

products in market and new products being clinically tested and launched. Distribution agreements

For

were entered into in both German and New Zealand and the Company successfully supported Levin

Health's receipt of ethics approval for Phase 2A clinical trial for chronic pain.

3. Net tangible assets per security

31 December 2021

31 December 2020

Net tangible asset backing per ordinary security

0.006

0.008

4.

Details of entities over which control has been gained or lost

4.1. Control gained over entities

N/A

use only

	4.2. Control lost over entities
N/A
5.	Dividends
Individual dividends per security
				Franked		Amount per
			Amount		security of
		Date dividend is	amount per
		per		foreign
		payable	security at
		security		source
			30% tax
					dividend
Interim dividend:
Current year	N/A	N/A	N/A		N/A
Previous year	N/A	N/A	N/A		N/A
6.	Dividend reinvestment plans

The dividend or distribution plans shown below are in operation.

N/A

The last date(s) for receipt of election notices for

the dividend or distribution plans.

N/A

For personal

7. Details of associates and joint entities

N/A

8. Foreign entities

N/A

9. If the accounts are subject to audit dispute or qualification, details are described below.

N/A

Sign here:

Date:

23 February 2022

	Managing Director
Print Name:	Oludare Odumosu

For personal use only

2021

HALF-YEAR FINANCIAL REPORT

31 DECEMBER 2021

Zelira Therapeutics Ltd

ABN 27 103 782 378

For personal use only

Zelira Therapeutics Ltd Half-Year Financial Report 31 December 2021

2

For personal use only

Contents

4	Directors' Report

8	Auditor's Independence
Declaration

Condensed Consolidated

9 Statement of

Comprehensive Income

10	Condensed Consolidated
Statement of Financial Position

11	Condensed Consolidated
Statement of Changes in Equity

12

13

24

25

27

Condensed Consolidated

Statement of Cash Flows

Notes to the Condensed Consolidated Financial Statements

Directors' Declaration

Independent Auditor's

Review Report

Corporate Directory

All announcements and financial reports are available on our website www.zeliratx.com

3

Zelira Therapeutics Ltd Half-Year Financial Report 31 December 2021